Freshfields advises Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio Therapeutics, with Paul, Weiss advising LogicBio, in a cash tender offer announced October 3, 2022.

The Sponsor

Loading page...

Freshfields advises Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio Therapeutics, with Paul, Weiss advising LogicBio, in a cash tender offer announced October 3, 2022. | The Sponsor - The Sponsor

$682.33 Million deal in Acquisition

Freshfields advises Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio Therapeutics, with Paul, Weiss advising LogicBio, in a cash tender offer announced October 3, 2022.

Freshfields

Overview

Paul, Weiss

Overview

Found it useful? Spread the word.